22:47 , Jan 5, 2018 |  BC Week In Review  |  Company News

Angiochem grants Xinogen Chinese rights to ANG1005

Angiochem Inc. (Montreal, Quebec) granted Xinogen Hong Kong Pharma Co. Ltd. exclusive, Chinese rights to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a...
12:08 , Jan 3, 2018 |  BC Extra  |  Company News

Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

ANG1005: Interim Phase II data

Interim data from 21 heavily pre-treated breast cancer patients with leptomeningeal carcinomatosis in an open-label, U.S. Phase II trial showed that ANG1005 led to 5 partial responses and 11 cases of stable disease as best...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

ANG1005: Phase II started

Angiochem began an open-label, U.S. Phase II trial to evaluate ANG1005 in up to 40 patients with progressive or recurrent HER2-positive breast cancer with brain metastases. Late last month, FDA granted Orphan Drug and Fast...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ANG1005: Phase II started

Angiochem began a U.S. Phase II trial to evaluate ANG1005 in up to 83 patients with recurrent high-grade glioma. Next quarter, Angiochem also plans to start a Phase II trial of ANG1005 in HER2-positive breast...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

ANG1005: Additional Phase II data

Angiochem said it will continue to develop ANG1005 based on data from 80 patients with brain metastases arising from metastatic breast cancer in the open-label, North American Phase II GRABM-B trial showing that the compound...
23:39 , Oct 21, 2013 |  BC Extra  |  Company News

Angiochem advances ANG1005 for cancer

Angiochem Inc. (Montreal, Quebec) said it will continue to develop ANG1005 (formerly GRN1005 ) based on additional Phase II data showing the compound produced responses in breast cancer patients with brain metastases. Last year, Geron...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Imetelstat: Additional Phase II data

Data from a pre-specified subgroup of 19 NSCLC patients whose tumors had short telomeres at baseline in the open-label, U.S. Phase II B012 trial in 116 patients showed that maintenance therapy with imetelstat significantly increased...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Imetelstat: Phase II data

Top-line data from 14 patients with ET who were refractory to or intolerant of conventional therapies in an open-label, international Phase II trial showed that imetelstat led to a complete response rate of 93% and...